7.65
1.29%
-0.10
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IBRX Giù?
Forum
Previsione
ImmunityBio Inc Borsa (IBRX) Ultime notizie
How Is The Market Feeling About ImmunityBio? - Investing.com UK
Investing.com UK
What the Options Market Tells Us About ImmunityBio - ImmunityBio (NASDAQ:IBRX) - Benzinga
Benzinga
Connecting the Dots of ANKTIVA's Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat ... - Business Wire
Business Wire
(IBRX) Proactive Strategies - Stock Traders Daily
Stock Traders Daily
ImmunityBio (NASDAQ:IBRX) Shares Down 4.2% - MarketBeat
MarketBeat
Investigation Alert Baxter International, Eagle Pharmaceuticals, BioXcel Therapeutics, and ImmunityBio: Johnson Fistel ... - GlobeNewswire
GlobeNewswire
Investigation Alert Baxter International, Eagle Pharmaceuticals, BioXcel Therapeutics, and ImmunityBio: - EIN News
EIN News
ImmunityBio (NASDAQ:IBRX) Trading Up 8.9% - MarketBeat
MarketBeat
Amid Biotech Pitfalls, this Stock Has Outperformed NVDA in the Last 3 Months - The Tokenist
The Tokenist
ImmunityBio Advances On the Anktiva Front - Los Angeles Business Journal
Los Angeles Business Journal
ImmunityBio First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Yahoo Finance
ImmunityBio (NASDAQ:IBRX) Shares Gap Down to $8.06 - MarketBeat
MarketBeat
ImmunityBio: Q1 Earnings Snapshot - Darien Times
Darien Times
Zurcher Kantonalbank Zurich Cantonalbank Has $141000 Stock Position in ImmunityBio, Inc. (NASDAQ:IBRX) - Defense World
Defense World
ImmunityBio (IBRX) Stock Jumps 43.2%: Will It Continue to Soar? - Yahoo Singapore News
Yahoo Singapore News
ImmunityBio Plans to Use Dunkirk Facility for Producing Cancer-Treating Drug - Chautauqua Today
Chautauqua Today
ImmunityBio (IBRX) Stock Jumps 43.2%: Will It Continue to Soar? - Yahoo News UK
Yahoo News UK
Dunkirk plant part of ImmunityBio plans for drug - Jamestown Post Journal
Jamestown Post Journal
Dunkirk plant part of ImmunityBio plans for drug - Jamestown Post Journal
Jamestown Post Journal
170000 Bladder Cancer Vaccine Doses Prepared by ImmunityBio - Precision Vaccinations
Precision Vaccinations
ImmunityBio says it's committed to Dunkirk - Buffalo News
Buffalo News
ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170000 Doses of ANKTIVA® - Tyler Morning Telegraph
Tyler Morning Telegraph
ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170000 Doses of ANKTIVA® - Business Wire
Business Wire
ANKTIVA for Non-Muscle Invasive Bladder Cancer (NMIBC), USA - Clinical Trials Arena
Clinical Trials Arena
ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170000 Doses of ANKTIVA® - The Bakersfield Californian
The Bakersfield Californian
ImmunityBio (NASDAQ:IBRX) Shares Down 12.6% - MarketBeat
MarketBeat
What's Going On With ImmunityBio Stock? - MSN
MSN
Serum Institute of India partners with ImmunityBio for global supply of BCG across all cancer types - BSI bureau
BSI bureau
ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin ... - Business Wire
Business Wire
ImmunityBio partners with Serum Institute for cancer treatment supply - Investing.com
Investing.com
Enhanced Bladder Cancer Vaccine Ships 1,000 Doses — Precision Vaccinations News - Precision Vaccinations
Precision Vaccinations
ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the ... - Business Wire
Business Wire
Check Out What Whales Are Doing With IBRX - ImmunityBio (NASDAQ:IBRX) - Benzinga
Benzinga
ImmunityBio shares target raised on Anktiva pricing strategy By Investing.com - Investing.com
Investing.com
US FDA approves ImmunityBio's bladder cancer therapy - Yahoo News Canada
Yahoo News Canada
What's Going On With ImmunityBio Stock? - ImmunityBio (NASDAQ:IBRX) - Benzinga
Benzinga
FDA approves local company's bladder cancer drug - The Business Journals
The Business Journals
ImmunityBio's ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG ... - geneonline
geneonline
Immunitybio's bladder cancer therapy, Anktiva, gets FDA approval - BioWorld Online
BioWorld Online
ImmunityBio's FDA Approval and Planned Equity Expansion - TipRanks.com - TipRanks
TipRanks
FDA Approve ImmunityBio Bladder Cancer Therapy - European Pharmaceutical Manufacturer
European Pharmaceutical Manufacturer
FDA clears ImmunityBio's bladder cancer drug at 2nd attempt - pharmaphorum
pharmaphorum
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non ... - Financial Times
Financial Times
FDA Action Alert: ImmunityBio, Aquestive, XOMA and More - BioSpace
BioSpace
Vanguard Group Inc. Buys 4,342,386 Shares of ImmunityBio, Inc. (NASDAQ:IBRX) - MarketBeat
MarketBeat
Eight PDUFA dates on deck in April - BioCentury
BioCentury
Is Immunitybio Inc (IBRX) Stock a Smart Value? - InvestorsObserver
InvestorsObserver
ImmunityBio shares target raised by Piper Sandler on potential approval By Investing.com - Investing.com
Investing.com
Sportradar Group Posts Upbeat Earnings, Joins Kingsoft Cloud, Braskem And Other Big Stocks Moving Higher On Wednesday
Benzinga
2 Stocks Under $20: Immunitybio and Lemonade - Schaeffers Research
Schaeffers Research
Capitalizzazione:
|
Volume (24 ore):